Gopal Rao, MD
Cardiovascular Disease · McDonough, GANPI 1083655203
Payments from drug & device makers
Across 103 payments — averaging $19.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$407
- Novartis$336
- Amarin Pharma, Inc.$154
- Merck$132
- AbbVie$113
- Abbott$95
- plus $742 from 18 others
What the payments were for
- Food & beverage$1,980100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 20 | $407 |
| Novartis | 21 | $336 |
| Amarin Pharma, Inc. | 8 | $154 |
| Merck | 8 | $132 |
| AbbVie | 4 | $113 |
| Abbott | 4 | $95 |
| Boehringer Ingelheim | 5 | $85 |
| Astellas Pharma US Inc | 4 | $66 |
| Johnson & Johnson | 4 | $62 |
| E.r. Squibb & Sons, L.L.C. | 3 | $60 |
| Abiomed | 2 | $53 |
| Edwards Lifesciences | 2 | $52 |
| Amgen | 3 | $50 |
| Angiodynamics, Inc. | 1 | $48 |
| Vital Connect, Inc | 2 | $47 |
| Alnylam Pharmaceuticals Inc. | 2 | $41 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $33 |
| Impulse Dynamics (USA) Inc. | 2 | $29 |
| Organogenesis Inc. | 1 | $25 |
| Bayer | 1 | $21 |
| Cvrx, Inc. | 1 | $20 |
| GSK | 1 | $18 |
| Lundbeck LLC | 1 | $17 |
| Medtronic | 1 | $13 |
How this compares
$1,980 in reported general payments places this provider in the 45th percentile of 640 cardiovascular disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ezetimibe | 11 | $262 |
| Atorvastatin Calcium | 22 | $180 |
| Metoprolol Succinate | 12 | $166 |
| Potassium Chloride | 11 | $144 |
| Carvedilol | 13 | $128 |
| Furosemide | 21 | $85 |
| Amlodipine Besylate | 11 | $43 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in McDonough
- Narendra SinghJohns Creek$5.4M
- Elizabeth OfiliAtlanta$4.5M
- Sanjay YadavAtlanta$3.7M
- Arshed QuyyumiAtlanta$3.4M
- Naresh ParikhNorcross$2.8M
- Nicolas ChronosEatonton$2.4M
- Bobby KhanAtlanta$1.7M
- Hunter ChampionColumbus$1.5M
- David SuhTucker$1.1M
- Michael MorrisAtlanta$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.